SAN DIEGO, Oct. 16 /PRNewswire-FirstCall/ -- Favrille, Inc. , a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced today that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, October 25, 2007 to discuss the Company's third quarter 2007 financial results. A press release reporting Favrille's third quarter 2007 financial results will be issued before the U.S. stock markets open on October 25, 2007.
A live audio webcast of management's presentation will be available on the Investor Relations section of the Company's web site at http://www.favrille.com. Alternatively, callers may participate in the conference call by dialing (866) 578-5788 or (617) 213-8057, passcode 49255440. A telephone replay of the call will also be available for 48 hours. The telephone replay can be accessed by dialing (888) 286-8010 or (617) 801-6888, passcode 47807048.
About Favrille, Inc.
Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId(R), is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell non-Hodgkin's lymphoma (NHL) and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.
pdespain@favrille.com
CONTACT: Pete De Spain, Director, Investor Relations & Corporate
Communications of Favrille, Inc., +1-858-526-2426, pdespain@favrille.com
Web site: http://www.favrille.com/
